Edoardo Galli

Edoardo Galli

Auto-generated profile, based on publicly available information

Edoardo Galli

Departments of Biomedicine and Clinical Research, University Hospital Basel and University of Basel, 4031 Basel, Switzerland

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
EGEdoardo Galli
Edoardo Galli
FHFelix J. Hartmann
Felix J. Hartmann
BSBettina Schreiner
Bettina Schreiner
FIFlorian Ingelfinger
Florian Ingelfinger
EAEirini Arvaniti
Eirini Arvaniti
BBBurkhard Becher
Burkhard Becher

7 November 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
FHFelix J. Hartmann
Felix J. Hartmann
RBRaphaël Bernard-Valnet
Raphaël Bernard-Valnet
CQClémence Quériault
Clémence Quériault
DMDunja Mrdjen
Dunja Mrdjen
LWLukas M. Weber
Lukas M. Weber
BBBurkhard Becher
Burkhard Becher
Narcolepsy type 1 is a devastating neurological sleep disorder resulting from the destruction of orexin-producing neurons in the central nervous system (CNS). Despite its striking association with the HLA-DQB1*06:02 allele, the autoimmune etiology of narcolepsy has remained largely hypothetical. Here, we compared peripheral mononucleated cells from narcolepsy patients with HLA-DQB1*06:02-matched healthy controls using high-dimensional mass cytometry in combination with algorithm-guided data analysis. Narcolepsy patients displayed multifaceted immune activation in CD4+ and CD8+ T cells dominated by elevated levels of B cell–supporting cytokines. Additionally, T cells from narcolepsy patients showed increased production of the proinflammatory cytokines IL-2 and TNF. Although it remains to be established whether these changes are primary to an autoimmune process in narcolepsy or secondary to orexin deficiency, these findings are indicative of inflammatory processes in the pathogenesis of this enigmatic disease.

16 February 2022 in Nature
Verified
Journal Article
Open access
PDF file
FIFlorian Ingelfinger
Florian Ingelfinger
LGLisa Ann Gerdes
Lisa Ann Gerdes
VKVladyslav Kavaka
Vladyslav Kavaka
SKSinduya Krishnarajah
Sinduya Krishnarajah
EFEkaterina Friebel
Ekaterina Friebel
BBBurkhard Becher
Burkhard Becher
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system underpinned by partially understood genetic risk factors and environmental triggers and their undefined interactions1,2. Here we investigated the peripheral immune signatures of 61 monozygotic twin pairs discordant for MS to dissect the influence of genetic predisposition and environmental factors. Using complementary multimodal high-throughput and high-dimensional single-cell technologies in conjunction with data-driven computational tools, we identified an inflammatory shift in a monocyte cluster of twins with MS, coupled with the emergence of a population of IL-2 hyper-responsive transitional naive helper T cells as MS-related immune alterations. By integrating data on the immune profiles of healthy monozygotic and dizygotic twin pairs, we estimated the variance in CD25 expression by helper T cells displaying a naive phenotype to be largely driven by genetic and shared early environmental influences. Nonetheless, the expanding helper T cells of twins with MS, which were also elevated in non-twin patients with MS, emerged independent of the individual genetic makeup. These cells expressed central nervous system-homing receptors, exhibited a dysregulated CD25–IL-2 axis, and their proliferative capacity positively correlated with MS severity. Together, our matched-pair analysis of the extended twin approach allowed us to discern genetically and environmentally determined features of an MS-associated immune signature.

17 January 2019 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
EGEdoardo Galli
Edoardo Galli
EFEkaterina Friebel
Ekaterina Friebel
FIFlorian Ingelfinger
Florian Ingelfinger
SUSusanne Unger
Susanne Unger
NNNicolás Gonzalo Núñez
Nicolás Gonzalo Núñez
BBBurkhard Becher
Burkhard Becher

26 July 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MDMartin Diebold
Martin Diebold
EGEdoardo Galli
Edoardo Galli
AKAndreas Kopf
Andreas Kopf
NSNicholas S R Sanderson
Nicholas S R Sanderson
ICIlaria Callegari
Ilaria Callegari
TDTobias Derfuss
Tobias Derfuss
Dimethyl fumarate (DMF) is an immunomodulatory treatment for multiple sclerosis (MS). Despite its wide clinical use, the mechanisms underlying clinical response are not understood. This study aimed to reveal immune markers of therapeutic response to DMF treatment in MS. For this purpose, we prospectively collected peripheral blood mononuclear cells (PBMCs) from a highly characterized cohort of 44 individuals with MS before and at 12 and 48 wk of DMF treatment. Single cells were profiled using high-dimensional mass cytometry. To capture the heterogeneity of different immune subsets, we adopted a bioinformatic multipanel approach that allowed cell population–cluster assignment of more than 50 different parameters, including lineage and activation markers as well as chemokine receptors and cytokines. Data were further analyzed in a semiunbiased fashion implementing a supervised representation learning approach to capture subtle longitudinal immune changes characteristic for therapy response. With this approach, we identified a population of memory T helper cells expressing high levels of neuroinflammatory cytokines (granulocyte–macrophage colony-stimulating factor [GM-CSF], interferon γ [IFNγ]) as well as CXCR3, whose abundance correlated with treatment response. Using spectral flow cytometry, we confirmed these findings in a second cohort of patients. Serum neurofilament light-chain levels confirmed the correlation of this immune cell signature with axonal damage. The identified cell population is expanded in peripheral blood under natalizumab treatment, substantiating a specific role in treatment response. We propose that depletion of GM-CSF–, IFNγ-, and CXCR3-expressing T helper cells is the main mechanism of action of DMF and allows monitoring of treatment response.

1 April 1991 in Acta Neurologica Scandinavica
Verified
Journal Article
Open access
PDF file
FLFrancesco Lolli
Francesco Lolli
GSGiuseppe Siracusa
Giuseppe Siracusa
MAM. P. Amato
M. P. Amato
LFL. Fratiglioni
L. Fratiglioni
GPG. Dal Pozzo
G. Dal Pozzo
LAL. Amaducci
L. Amaducci
We studied the intrathecal synthesis of free kappa, free lambda immunoglobulin light chains and of IgM in 33 consecutive patients with possible or probable MS at the time of their first diagnosis. Nineteen patients presented free kappa or lambda light chain bands in CSF after agarose isoelectric focusing, protein transfer to nitrocellulose and immunostaining with specific antisera. Nineteen patients had increased CSF levels of free kappa light chains as measured with a competitive ELISA. Fourteen had an increased IgM index, as evaluated with a sandwich ELISA. Twenty-six patients displayed CSF oligoclonal IgG bands in CSF and 25 had cerebral magnetic resonance imaging lesions suggestive of MS. The local production of free immunoglobulin light chains and IgM is often detected in the CSF of patients with early MS.